Financial News Feed

Stronger Sell Today ADMS ranks #3821 as SELL CANDIDATE. Weaker Sell
Today ADMS ranks #3821 as SELL CANDIDATE.

ADMS stock Adamas Pharmaceuticals

ADMS stock
Adamas Pharmaceuticals

The stock of Ultra Clean Holdings, Inc. (NASDAQ:UCTT) is a huge mover today! The stock increased 5.56% or $0.58 during the last trading session, reaching Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Rat...

Read more

Wall Street brokerages forecast that Adamas Pharmaceuticals Inc (NASDAQ:ADMS) will report earnings per share of ($1.13) for the current quarter, according to Zacks Investment Research. Five analysts h...

Read more

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Ratings CoverageAmong 7 analysts covering Adamas Pharmaceuticals (NASDAQ:ADMS), 4 have Buy rating, 1 Sell and 2...

Read more

Adamas Pharmaceuticals Inc (NASDAQ:ADMS) has received an average rating of “Hold” from the eleven brokerages that are currently covering the company, MarketBeat reports. Two investment analysts ha...

Read more

Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) and Collegium Pharmaceutical Inc. (NASDAQ:COLL) compete with each other in the Drugs – Generic sector. We will analyze and contrast their profitability, ana...

Read more

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) making news as their share price hit $7.99 at the end of the most recent trading day. Considering that price volatility is equivalent to risk, a commodity’...

Read more

The stock of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) is a huge mover today! It closed at $7.99 lastly. It is down 51.24% since March 20, 2018 and is Sentiment for Allergan Inc (AGN)Allergan Inc (AG...

Read more

Granite Point Capital Management Lp decreased Adamas Pharmaceuticals Inc (ADMS) stake by 71.85% reported in 2018Q4 SEC filing. Granite Point Capital Management Gardner Lewis Asset Management LP decrea...

Read more

Adamas Pharmaceuticals, Inc. (NasdaqGM:ADMS) has an ERP5 rank of 17020. The ERP5 Rank is an investment tool that analysts use to discover undervalued companies. It looks at the stock’s Price to Book...

Read more

SkyWest Inc (NASDAQ:SKYW) is expected to pay $0.12 on Apr 4, 2019. (NASDAQ:SKYW) shareholders before Mar 28, 2019 will receive the $0.12 dividend. SkyWest Adamas Pharmaceuticals Inc (NASDAQ:ADMS) had ...

Read more

Wall Street brokerages expect Adamas Pharmaceuticals Inc (NASDAQ:ADMS) to report $12.78 million in sales for the current quarter, according to Zacks. Five analysts have issued estimates for Adamas Pha...

Read more

Adamas Pharmaceuticals, Inc. (NasdaqGM:ADMS) currently has a Value Composite score of 96. Similarly, the Value Composite Two (VC2) is calculated with the same ratios, but adds the Shareholder Yield. T...

Read more

Adamas Pharmaceuticals, Inc. (NasdaqGM:ADMS) has a current MF Rank of 18887. Developed by hedge fund manager Joel Greenblatt, the intention of the formula is to spot high quality companies that are tr...

Read more

This report focuses on the global Advanced Distributed Management System (ADMS) status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Advance...

Read more

HEXO Corp. (NYSEAMERICAN:HEXO) and Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) compete against each other in the Drugs - Generic sector. We will contrast them...

Read more

News Feed powered by

Proudly made at

Rise Vilnius
in partnership with
Barclays Bank